相关实验视频
Updated: May 22, 2025
09:16
Assessment of Kidney Function in Mouse Models of Glomerular Disease
Published on: June 30, 2018
17.5K
-葡萄糖共运输体2 抑制剂在糖尿病病及其他疾病中
Zein Alabdin Hannouneh1, C Elena Cervantes2, Mohamad Hanouneh2,3
1Faculty of Medicine, Al Andalus University for Medical Sciences, Tartus, Syria.
Glomerular diseases
|March 14, 2025
概括
-葡萄糖携带载体2抑制剂 (SGLT2is) 在糖尿病病和心力衰竭患者中,除了降低血糖之外,还提供了显著的和心血管益处. 这些药物减轻炎症和纤维化,改善患者的治疗结果.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- -葡萄糖共传输体2抑制剂 (SGLT2is) 已成为糖尿病病 (DKD) 和心力衰竭 (HF) 的转化疗法.
- 它们的影响超出了血糖控制范围,提供了显著的脏和心血管保护益处.
- 本综述综合了目前对SGLT2的机制和临床疗效的理解.
研究的目的:
- 检查SGLT2is. 的脏和心血管保护作用背后的机制性途径.
- 评估SGLT2is在治疗DKD和HF方面的临床疗效.
- 审查支持SGLT2is在当前临床指南中的作用的证据.
主要方法:
- 使用PubMed.com进行了全面的文献审查.
- 确定并分析了SGLT2抑制剂的关键临床试验和机制研究.
- 审查的重点是详细说明SGLT2is对功能,心血管事件和相关途径的影响的研究.
主要成果:
- SGLT2is诱导葡萄糖尿和尿,缓解高血糖引起的并发症.
- 它们减少了白色素尿,增强了管状功能,调节了红色素质形成,减少了炎症和纤维化.
- 主要的临床试验显示,2型糖尿病患者的脏和心血管事件显著减少.
结论:
- 通过向多种致病途径,SGLT2is对于管理DKD和HF至关重要.
- 目前的指导方针包括SGLT2is用于DKD和HF管理,在非糖尿病人群中有新兴的好处.
- 需要进一步的研究来阐明SGLT2的多方面的机制,并扩大其治疗应用.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
148
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
148
01:55Secondary Active Transport
117.2K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
117.2K
01:23Dipeptidyl Peptidase 4 Inhibitors
153
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
153
01:27Glucose Transporters
22.3K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.3K
01:06Oral Hypoglycemic Agents: Glinides
124
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
124
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
140
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
140